Navigation Links
Medical Marijuana Inc. Product, CanChew Bio-Technologies
Date:8/23/2012

SAN DIEGO, Aug. 23, 2012 /PRNewswire/ -- Medical Marijuana Inc. (OTC: MJNA), a leading hemp industry innovator, is pleased to welcome Dr. Philip Van Damme, Director for CanChew Biotechnologies, to Small Cap Voice's Internet radio network. Dr. Van Damme, a Netherlands-trained surgeon, is eager to share why and how he invented the revolutionary Non-THC CanChew gum. Its tremendous medical potential will offer a new treatment for pain-afflicted people in the U.S. and beyond.

The interview below, which is conducted by Small Cap Voice Internet radio host Stuart T. Smith, provides valuable insight into the history of CanChew Biotechnologies, which will announce a soft release product launch on September 15th in the U.S. with international markets to follow.

In the program, Dr. Van Damme points out that an important part of CanChew lies in its non-stigmatizing, legal medical delivery system. Unlike the harmful means of smoking medicinal marijuana, this specialized gum transports Non-THC cannabinoids through the body with the simple ease of the societally accepted act of chewing gum.

Its potential value to patients? Immense, Dr. Van Damme says. Chronic pain suffers, beginning and end stage cancer patients, even a person with anorexia, can see relief with CanChew. Dr. Van Damme adds that he put his heart into developing this product because patients in deep pain continuously confront him. He believes CanChew is a new vehicle-unlike any other on the market-that can offer them relief. As revenues of the product grow, he plans on using a portion to reinvest in scientific studies that continue to establish its medicinal potency.

Logo: http://www.smallcapvoice.com/mjna/logo.jpg

MP3 Link: http://smallcapvoice.com/blog/wp-content/uploads/mjna-8-22-12.mp3

Podcast Link: http://smallcapvoice.com/blog/8-22-12-smallcapvoice-interview-with-medical-marijuana-inc-pink-sheets-mjna

Stock Quote: http://app.quotemedia.com/quotetools/clientForward?targetURL=http://www.smallcapvoice.com/Small-Cap-Stock-Quotes.html&action=showDetailedQuote&symbol=MJNA

About CanChew

CanChew® is a unique, socially acceptable, patient friendly, taste masked and convenient delivery format for delivery of cannabis/cannabinoid(s) based pharmaceuticals. The delivery of these medications via the oral mucosa provides for rapid and near complete absorption directly into the systemic circulation. This leads to rapid onset of effects and increased bioavailability. Pre-systemic metabolism is thus avoided. This system of delivery offers clearly improved economic opportunities compared to alternative drug delivery routes.

About Medical Marijuana, Inc.

Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally friendly, economically sustainable businesses, while increasing shareholder value.

Medical Marijuana Inc. does not grow, sell or distribute any substances that violate United States Law or the controlled substance act.

For more information, please visit the company's website at: www.MedicalMarijuanaInc.com

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration (FDA). These products and statements are not intended to diagnose, treat, cure, or prevent any disease.

Corporate Contact:
Medical Marijuana, Inc.
Toll Free: 888-OTC-MJNA (888-682-6562)
www.medicalmarijuanainc.com
www.facebook.com/mjnainc

Investor Relations Contact:
Stuart T. Smith
SmallCapVoice.Com, Inc.
P. 512-267-2430
F. 512-267-2530
Email: ssmith@smallcapvoice.com
Skype: SmallCapVoice.com
AIM: SmallCapVoice7

 


'/>"/>
SOURCE Medical Marijuana Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. The Leukemia & Lymphoma Society Awards $12 Million in Research Grants in Four Critical Areas of Unmet Medical Need
2. Elsevier / MEDai Names Dr. Peter Edelstein as Chief Medical Officer and Dr. Gerald Osband as Director of Product Strategy
3. Former FDA Inspectors Train Medical Device, Pharmaceutical Companies How to Prepare for FDA Inspections of Their Quality Systems
4. Department of Defense Exercises Options Under Contract for Nerve Agent Medical Countermeasure Program
5. Chicago Celebrates First Informatics Week, Co-Chaired by Intelligent Medical Objects and Northwestern University
6. MAQUET MEDICAL SYSTEMS USA LAUNCHES NEW TEGRIS O.R. INTEGRATION SYSTEM FOR ADVANCED SURGICAL CONTROL
7. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
8. Leading India-USA based CRO Announces Data Management/EDC, Medical Writing Milestone
9. UMass Amherst, Harvard experts say better systems needed for medical device cybersecurity
10. Putting Medical Knowledge at the Forefront of Business
11. Agendia Welcomes Dr. Mark Gittleman to Expanding Medical Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)...   Boston Biomedical , an industry leader in ... stemness pathways, will feature data from two clinical studies ... ASCO Gastrointestinal Cancers Symposium, held from January 19-21, in ... Napabucasin is an orally-administered investigational agent designed to inhibit ... stem cells (CSCs) possess the property of stemness – ...
(Date:1/18/2017)... ... January 18, 2017 , ... Whitehouse ... expertise. Within Albany Molecular Research, Inc. (AMRI), the scientific staff dedicated to Extractables ... is planned for further growth in 2017. Extractable & Leachable evaluations have become ...
(Date:1/18/2017)... Chicago, IL (PRWEB) , ... January 18, 2017 ... ... auction on January 24th, 2017, to sell research and genetic testing lab equipment ... of service in the Northwest and Northeast regions of the United States. This ...
(Date:1/18/2017)... 18, 2017  Caris Life Sciences, a leading ... the largest private funder of pancreatic cancer research, ... the impact of immunotherapy in the treatment of ... services to identify potential trial candidates based on ... physicians and study investigators. The Lustgarten Foundation is ...
Breaking Biology Technology:
(Date:12/19/2016)... España y TORONTO , 19 de diciembre de ... Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo ... varios tipos de tumor en 2017, con múltiples sitios previstos a ... ... con objetivo en el factor inhibidor de leucemia (LIF), una citoquina ...
(Date:12/15/2016)...   WaferGen Bio-systems, Inc. (NASDAQ: ... today that on December 13, 2016, it received a ... Stock Market LLC which acknowledged that, as of December ... stock had been at $1.00 or greater for ten ... Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/12/2016)... , Dec. 12, 2016  Researchers at Trinity ... for graphene by combining the material with Silly ... sensitive pressure detector able to sense pulse, blood ... small spider.  The research team,s ... be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):